Choose the medication best suited to your individual needs and consult your doctor for personalized advice.
Both Sildenafil (Revatio) and Tadalafil (Adcirca) treat pulmonary arterial hypertension (PAH), improving exercise capacity and reducing symptoms. However, they differ in their mechanisms and potential side effects.
Sildenafil inhibits phosphodiesterase type 5 (PDE5), leading to increased nitric oxide levels and improved blood vessel dilation. Common side effects include headaches, flushing, and dyspepsia. Its half-life is approximately 4 hours, requiring more frequent dosing.
Tadalafil, also a PDE5 inhibitor, offers a longer duration of action with a half-life around 17.5 hours. This allows for once-daily dosing, potentially improving adherence. Side effects are similar to Sildenafil, but the frequency and severity may vary.
Regarding efficacy, clinical trials show both drugs improve PAH symptoms. The optimal choice depends on individual tolerance, response, and lifestyle. For patients who prefer a once-daily regimen, Tadalafil may be advantageous. For others, Sildenafil’s shorter half-life may be preferable.
Always discuss potential drug interactions with your physician before starting either medication. Regular monitoring of blood pressure and other relevant parameters is important during treatment.
This information is for educational purposes only and does not constitute medical advice. Consult your doctor before making any decisions related to your health.
